Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

Lakeside Holding Limited ("Lakeside" or the "Company") , a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market operating under the brand ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a ...

We examine how to create a brand mood board – what they are, why they matter and how to make boards that capture the essence of your brand. Have you considered how the best brands can create a ...

Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised ...

But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...